BRESCIANI ELENA

Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R., et al. (2025). Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases. BIOMÉDECINE & PHARMACOTHÉRAPIE, 186 [10.1016/j.biopha.2025.118044]. Detail

Ranzani, A., Castelli, F., Di Biagio, A., d'Arminio Monforte, A., D'Avolio, A., Soria, A., et al. (2024). Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects. HIV MEDICINE, 25(4 (April 2024)), 491-497 [10.1111/hiv.13600]. Detail

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Selected Growth Hormone Secretagogues (GHS) as disease modifiers in an in vitro model of Amyotrophic Lateral Sclerosis: a proof-of-concept study. Intervento presentato a: 9th European Congress of Pharmacology (EPHAR 2024), Atene, Grecia. Detail

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Potential application of Growth Hormone Secretagogues (GHS) for Amyotrophic Lateral Sclerosis (ALS) treatment: mechanisms of action and neuroprotective effects characterization in human SH-SY5Y SOD1G93A cells. Intervento presentato a: Innovazione e malattie rare: dalla ricerca preclinica al paziente, Bari, Italia. Detail

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Sartori, E., Omeljaniuk, R., et al. (2024). Selected Growth Hormone Secretagogues (GHS) as promising therapeutical approach for Amyotrophic Lateral Sclerosis: a proof-of-concept study. Intervento presentato a: 42° Congresso Nazionale SIF. Science today for a better medicine tomorrow, Sorrento, Italia. Detail